Fresenius SE & Co. SWOT & PESTLE Analysis
COMPANY PROFILE -Fresenius SE & Co.
Business Sector :Pharma & Healthcare
Operating Geography :Germany, Europe, Global
About Fresenius SE & Co. :
Fresenius SE & Co. KGaA is a health care company primarily providing products and services for dialysis, hospitals along with inpatient and outpatient medical care. It was founded in 1912 by Eduard Fresenius. It is headquartered in Germany. The company is one of the world’s leading healthcare companies serving more than 100 countries around the globe. The Fresenius Group includes 4 independent business segments with each segment being active in a major area of growth in healthcare. The 4 groups are Fresenius Medical care which is the world leader in kidney failure treatment, Fresenius Helios which is Europe’s largest private hospital operator, Fresenius Kabi which supplies essential drugs and medical services to help critically ill patients and Fresenius Vamed which plans and manages healthcare facilities. The Group employed over 294,000 employees at the start of 2020.Fresenius always keeps the patients first which has remained their unique selling proposition. They have been working for more than 100 years to save lives and improve the quality of life of their patients. With strong focus on innovation and efficiency, they have made quality healthcare services accessible to large number of people and work towards finding better solutions thus contributing to medical progress and better patient care. Their commitment to future is captured by “Forward Thinking Healthcare”: better medicine for more people.
Fresenius mission statement reads as “Better medicine and health care services for even more people”.
Fresenius SE & Co. Revenue :
€ 35.5 billion – FY ended 31st Dec 2019
€ 33.5 billion - FY ended 31st Dec 2018
Competitive Analysis of Fresenius SE & Co.
| Strengths | Weaknesses |
| 1. Strong focus on research and development 2. World’s leading products and service provider for kidney patients 3. Consecutive record year with strong financial performance 4. Significant progress across four business groups | 1. Voluntary recall of lots due to presence of particulate matter |
| Opportunities | Threats |
| 1. Increasing global dialysis market 2. Increasing opportunities in health care sector 3. Expanding the regional presence 4. Broadening the products and services business | 1. Impact of regulatory changes on Fresenius Helios 2. Changes in health care and reimbursement systems related regulations 3. Re-entry of competitors into the U.S. market for generic IV drugs |
Complete Report
USD 27
- with PayPal
- with Debit/Credit card
Safe and secure payments
Detailed SWOT Analysis of Fresenius SE & Co.
Strength
1. Strong focus on research and development: Being one of the leading services providers in the healthcare segment, Fresenius attaches great importance to research and development. The Group stays updated with all latest technology and developments so as to serve the patients better and hence is incessantly involved in research. Fresenius Kabi in 2019 opened a research and development center in Switzerland for biosimilars. A biosimilar is a drug which is similar to another approved biologic drug. The German medical care company invested around €15 million which will further help in strengthening the company’s capability to develop new biosimilars specially in the areas of autoimmune and diseases and oncology. Fresenius Kabi formed a joint venture along with Bio-Techne and Wilson Wolf to support researchers and biopharmaceutical companies in cell and gene therapy fields. Fresenius Medical Care also expanded its clinical research activities by expanding the offerings of Frenova Renal Research, a subsidiary, which was previously limited to North America, to Europe, Middle east and Africa and Latin America.
The remaining section of “Strength” is available only in the 'Complete Report' on purchase.
Weakness
This section is available only in the 'Complete Report' on purchase.
Opportunity
1. Increasing global dialysis market:The global dialysis market has been increasing at a high rate with each passing year. In 2019, this market was approximated to be worth €80 billion and saw a growth of around 4%. Approximately 4.3 million people were treated worldwide with chronic renal failure out of which 3.5 million received dialysis treatments and about 815,000 were living with transplanted kidney. The major growth factor for the increasing dialysis market is the increasing number of patients with diabetes and blood pressure since these 2 diseases often precede the onset of chronic kidney failure. The number of dialysis patients increased by 6% worldwide. Around 10% of the worldwide dialysis patients are being treated by Fresenius Medical care. Fresenius Medical care is the leading provider of dialysis products in the world with a market share of 36%. With the momentous growth of the global dialysis market, Fresenius is well positioned to see healthy growth. https://www.fresenius.com/financial_reporting/Fresenius_Annual_Report_2019.pdf Page 47, 72
The remaining section of “Opportunity” is available only in the 'Complete Report' on purchase.
h2>ThreatsThis section is available only in the 'Complete Report' on purchase.
Major Competitors :
Major Brands :
- Fresenius Medical Care
- Fresenius Helios
- Fresenius Kabi
- Fresenius Vamed
Complete Report
USD 27
- with PayPal
- with Debit/Credit card
Safe and secure payments
Check Out Analysis of Other Relevant Companies
TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?
References used in Fresenius SE & Co. Analysis Report
1. Fresenius Medical Care expands collaboration with U.S. insurer Humana -
https://www.fresenius.com/
2. Trump Administration Announces Plans To Shake Up The Kidney Care Industry -
https://www.npr.org/sections/health-shots/2019/07/10/740276389/trump-
administration-announces-plans-to-shake-up-the-kidney-care-industry
3. Fresenius Kabi's Recall of Ketorolac Results In QuVa Pharma®
Recall of Compounded Sterile Product (R.E.C.K.) -
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/
fresenius-kabis-recall-ketorolac-results-quva-pharmar-recall-compounded-sterile-product-reck
4. Annual Report 2019 -
https://www.fresenius.com/financial_reporting/Fresenius_Annual_Report_2019.pdf
The detailed complete set of references are available on request in the 'Complete report' on purchase.
How to Reference This Page?
You can use the following in your reference section in order to give credit to the source. For different referencing styles and detailed guidelines, please click here.
Fresenius SE & Co. SWOT & PESTLE Analysis - SWOT & PESTLE.COM
SWOT & PESTLE.com (2020). Fresenius SE & Co. SWOT & PESTLE Analysis - SWOT & PESTLE.com. [online] Available at: https://www.swotandpestle.com/fresenius-se-co/ [Accessed 28 Oct, 2020].
In-text: (SWOT & PESTLE.com, 2020)
Copyrights and Disclaimer
Fresenius SE & Co. SWOT & PESTLE analysis has been conducted by Sushree Lasyamayee and reviewed by senior analysts from Barakaat Consulting.
Copyright of Fresenius SE & Co. SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.
